

ALCON AG

ISIN: CH0432492467

WKN: H01301128

Overview

| | |
|------------|-------|
| -- | |
| Price | - |
| Difference | - (-) |

| | |
|---------------------------|------------------------------------|
| General attributes | |
| ISIN | CH0432492467 |
| Symbol | ALC |
| Exchange | - |
| Currency | - |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 42,447 EUR |
| Benchmark | SWISS MARKET INDEX |

| | |
|--------------------|---|
| Market data | |
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | - |
| High | - |
| Low | - |
| Close (prev. day) | - |
| VWAP | - |
| Volume (pcs) | - |
| Trading volume | - |
| Number of trades | - |
| Last size | - |

| | |
|----------------------------|----|
| Futures and Options | |
| Related Futures | 30 |
| Related Options | - |

| | |
|--------------------------|---|
| PDF Downloads | |
| Company report: ALCON AG |  |



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research

| on sector | | on market | |
|------------|---|-----------------------|---|
| Date | | Headline | Download |
| 2024/07/24 |  | Global Equity Ratings |  |
| 2024/07/12 |  | Global Equity Ratings |  |
| 2024/06/21 |  | Global Equity Ratings |  |
| 2024/06/14 |  | Global Equity Ratings |  |
| 2024/05/29 |  | Global Equity Ratings |  |

Details

| | |
|------------|-------|
| -- | |
| Price | - |
| Difference | - (-) |

General attributes


| | |
|----------------|------------------------------------|
| ISIN | CH0432492467 |
| Symbol | ALC |
| Exchange | - |
| Currency | - |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 42,447 EUR |
| Benchmark | SWISS MARKET INDEX |

Market data

| | |
|-------------------|---|
| Bid (Bid size) | - |
| Ask (Ask size) | - |
| Open | - |
| High | - |
| Low | - |
| Close (prev. day) | - |
| VWAP | - |
| Volume (pcs) | - |
| Trading volume | - |
| Number of trades | - |
| Last size | - |

Performance and Risk

| | 6m | 1Y | 3Y |
|-------------|------|------|------|
| Perf (%) | - | - | - |
| Perf (abs.) | - | - | - |
| Beta | 0.63 | 0.74 | 0.88 |
| Volatility | - | - | - |



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

| | |
|---|--------|
| Ø price 5 days Ø volume 5 days (pcs.) | -- (-) |
| Ø price 30 days Ø volume 30 days (pcs.) | -- (-) |
| Ø price 100 days Ø volume 100 days (pcs.) | -- (-) |
| Ø price 250 days Ø volume 250 days (pcs.) | -- (-) |
| YTD High date | -- (-) |
| YTD Low date | -- (-) |
| 52 Weeks High date | -- (-) |
| 52 Weeks Low date | -- (-) |

Arbitrage views

| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
|---|------------|-------|-----------|-----------------------|------------------|
| SIX Swiss Exchange | 2024/07/26 | 17:30 | 83.00 CHF | 53.25 | 3,768 |
| NYSE | 2024/07/26 | 22:00 | 93.37 USD | 108.63 | 14,201 |
| London Stock Exchange European Trade Reporting | 2024/07/26 | 17:20 | 81.26 CHF | 0.21 | 6 |
| Hanover | 2019/06/28 | 08:00 | 52.91 EUR | 0.00 | 2 |
| Hamburg | 2019/ | 12:29 | 53.43 EUR | 0.01 | 4 |

| | | | | | | |
|-------------|----------------|-------|-------|-----|------|----|
| | 06/28 | | | | | |
| Frankfurt | 2019/ 06/28 | 17:10 | 54.07 | EUR | 0.06 | 23 |
| Duesseldorf | 2019/ 06/28 | 11:10 | 53.10 | EUR | 0.00 | 2 |
| Berlin | 2019/ 06/28 | 18:47 | 54.31 | EUR | 0.00 | 7 |

Company profile

Company Logo



Contact Details

ALCON AG

--

Royce Bedward, Chemin de Blandonnet 8 -
1214 Genf

Telefon: +41-817-293-04-50

Fax: +41-817-916-26-52

E-mail: -

PDF Downloads

Company report: ALCON AG



Company Profile

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.

Members of Management Board

| | |
|--------------------|-------------------------------|
| David J. Endicott | Chairman of Managing Board |
| Ian Bell | Member of Executive Committee |
| Laurent Attias | Member of Executive Committee |
| Rajkumar Narayanan | Member of Executive Committee |
| Sergio Duplan | Member of Executive Committee |
| Sue-Jean Lin | Member of Executive Committee |
| Tim Stonesifer | Member of Executive Committee |

Board of directors

| | |
|---------------------------|--------------------------------------|
| Arthur Cummings | Member of the administrative board |
| Bono Raquel Cruz | Member of the administrative board |
| Dieter Spälti | Member of the administrative board |
| D. Grossman | Member of the administrative board |
| Ines Pöschel | Member of the administrative board |
| Karen May | Member of the administrative board |
| Lynn Bleil | Member of the administrative board |
| Scott Maw | Member of the administrative board |
| Thomas Heinrich Glanzmann | Member of the administrative board |
| F. Ball | Chairman of the administrative board |